LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

19.54 -1.36

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.46

Massimo

20.3

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+103.52% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-77M 1.8B
Apertura precedente	20.9
Chiusura precedente	19.54

Notizie sul Sentiment di mercato

By Acuity

50%

138 / 344 Classifica in Healthcare

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mag 2026, 21:33 UTC

Utili

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mag 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mag 2026, 20:18 UTC

Utili

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mag 2026, 23:49 UTC

Discorsi di Mercato

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mag 2026, 23:39 UTC

Discorsi di Mercato

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mag 2026, 23:34 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 mag 2026, 23:08 UTC

Discorsi di Mercato

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mag 2026, 22:21 UTC

Discorsi di Mercato

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mag 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mag 2026, 21:08 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mag 2026, 21:02 UTC

Utili

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mag 2026, 20:59 UTC

Acquisizioni, Fusioni, Takeovers

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mag 2026, 20:55 UTC

Utili

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

27 mag 2026, 20:48 UTC

Utili

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mag 2026, 20:45 UTC

Utili

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mag 2026, 20:34 UTC

Acquisizioni, Fusioni, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

27 mag 2026, 20:32 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mag 2026, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mag 2026, 20:30 UTC

Utili

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mag 2026, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mag 2026, 20:22 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:16 UTC

Utili

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mag 2026, 20:13 UTC

Utili

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mag 2026, 20:13 UTC

Utili

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mag 2026, 20:12 UTC

Utili

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

103.52% in crescita

Previsioni per 12 mesi

Media 40.5 USD 103.52%

Alto 57 USD

Basso 29 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

138 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.